On Monday, Natera received a positive adjustment to its Relative Strength (RS) Rating, from 79 to 82.
Hone Your Stock-Picking Skills By Focusing On These Factors
IBD's unique RS Rating tracks technical performance by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
Decades of market research reveals that the best stocks tend to have an RS Rating north of 80 as they begin their biggest climbs.
Natera is working on a consolidation with a 183.00 buy point. See if it can break out in heavy trading. Keep in mind that it's a later-stage consolidation, and those entail more risk.
The company posted 0% EPS growth last quarter, while sales growth came in at 36%.
The company holds the No. 12 rank among its peers in the Medical-Services industry group. Hims & Hers Health, Option Care Health and Progyny are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
